scholarly journals LYGIAGREČIOS PREKYBOS RIBOJIMO FARMACIJOS SEKTORIUJE VERTINIMAS

Teisė ◽  
2013 ◽  
Vol 86 ◽  
pp. 144-159
Author(s):  
D. Miniotas
Keyword(s):  
Pharmaceutical Industry ◽  
Market Integration ◽  
Negative Attitude ◽  
Competition Law ◽  
Internal Market ◽  
Vertical Restraints ◽  
Legal Environment ◽  
Parallel Trade ◽  
Pharmaceutical Sector

Straipsnyje nagrinėjamas vienas iš „sunkiųjų“ vertikaliųjų apribojimų konkurencijos teisėje – lygiagrečios prekybos draudimas (ribojimas), koncentruojantis į tokio pobūdžio susitarimų vertinimą farmacijos sektoriaus kontekste. Straipsnyje atskleidžiama, kad dėl specifinės ekonominės ir teisinės farmacijos sektoriaus aplinkos lygiagrečios prekybos ribojimo susitarimai ne visada turėtų būti laikomi antikonkurenciniais. Diskutuojama, kiek yra pagrįsta, kad tokio pobūdžio susitarimų itin neigiamas vertinimas yra labiau nulemtas Europos Sąjungos vidaus rinkos integracijos tikslo nei teisinės ar ekonominės logikos.Te article examines one of the hardcore vertical restraints in competition law – prohibition (restriction) of parallel trade, with the focus on the assessment of such agreements within the context of pharmaceutical industry. The article discloses that due to the very specific economical and legal environment of the pharmaceutical sector, agreements restricting parallel trade should not be condemned as anticompetitive in all cases. It is discussed whether it is reasonable that extremely negative attitude towards such agreements is more conditioned upon the European Union’s internal market integration goal than legal or economic logic.

Pharmacist for a Healthy India – Swasth Bharath

2016 ◽  
Vol 9 (2) ◽  
pp. 3151-3154
Author(s):  
G. N. Singh
Keyword(s):  
Pharmaceutical Industry ◽  
Research And Development ◽  
Healthcare System ◽  
Scientific Knowledge ◽  
Health Sector ◽  
High Technology ◽  
Pharmaceutical Sector ◽  
The Public ◽  
Pharmacy Council ◽  
Global Player

India has emerged as a global player for pharmaceuticals. The pharmaceutical revolution of 1970-90 of Indian Pharma Industry had demonstrated that India could be self-sufficient in the manufacture of essential drugs at affordable prices. The turnover of Indian Pharmaceutical is over $30 billion in 2015 including $15 billion in exports.  It was a great honor to preside the 67th Indian pharmaceutical congress held in Mysore. The topic of Pharmacists for a Healthy India is close to my heart and being a regulator myself, I feel that the Pharmacy fraternity can play a much larger role in contributing to the healthcare system in India. Pharmacist as such are involved in a big way in the regulation of drugs, be it manufacture, be it sale or research and development. A contribution of the Pharmacists is there at every stage till the drug reaches the consumer safely. For this purpose, the society needs a pool of well qualified and experienced pharmacists, which requires regular updating of their knowledge to keep pace with the developments taking place in the pharmaceutical sector. The advancements in technology and the emerging challenges in the health sector require pharmacists to shoulder the responsibilities towards the utilization of scientific knowledge in the use of modern medicines and the protection of the public against dangers of wrong use of drugs. The Pharmacy Council of India on its part will have to ensure that the courses offered for creating a high technology based are calibrated in such a way that the education and skills developed suit to the requirements of the Pharmaceutical Industry as well as needs to the patients

scholarly journals A Study on SWOT Analysis of Pharmaceutical Industry: The Bangladesh Context

2013 ◽  
Vol 2 (2) ◽  
pp. 200-208
Author(s):  
Meem Rafiul Hoq ◽  
Md. Ali Ahsan ◽  
Tanim–A Tabassum
Keyword(s):  
Pharmaceutical Industry ◽  
Swot Analysis ◽  
Jel Classification ◽  
Economic Factors ◽  
Pharmaceutical Sector ◽  
Threat Analysis ◽  
Industry Sector ◽  
Classification Code ◽  
Large Size ◽  
The Future

Pharmaceutical industry is one of the most important sector in Bangladesh. It is the only industry, which has its own strong manufacturing capabilities to produce the pharmaceuticals product. In this study it is tried to find out what types of strengths, weaknesses, opportunities and threats the pharmaceuticals companies face in Bangladesh. There are about 250 pharmaceuticals firms in Bangladesh. Among them some companies are the large size and more sophisticated. Some companies are small sizes and traditional qualities. A few companies dominate the whole medicine market. So they have to face severe competition in pharmaceuticals market. SOWT (Strength, Opportunity, Weakness, and Threat) analysis of any industry sector investigates the important factors that are possibility of the industry and influencing the companies operating in that sector. The purpose of this study is to analyze the pharmaceutical sector of Bangladesh using the framework of SWOT. This paper brings to light on the SWOT analysis of pharmaceuticals industry in Bangladesh and provided some valuables suggestions to overcome the weaknesses and threats, there are some suggestions to utilize the strengths and opportunities properly. Through this study the researchers try to discuss the affect of various macro-economic factors of strength, opportunity, weakness, and threat aspect on the industry and its related problems and prospects for the future. JEL Classification Code: O25; O25

scholarly journals Effect of Financial Performance on Profitability in Indian Pharmaceutical Companies

2019 ◽  
Vol 8 (6) ◽  
pp. 4910-4916
Keyword(s):  
Pharmaceutical Industry ◽  
Financial Performance ◽  
National Economy ◽  
Pharmaceutical Companies ◽  
Government Control ◽  
Pharmaceutical Sector ◽  
Drug Store ◽  
Indian Pharmaceutical Industry

The total Indian pharmaceutical sector is exceedingly divided with in excess of 20,000 enlisted units. It has spread drastically over the most recent two decades. The pharmaceutical and the chemical industries in India is an amazingly separated market with solid value rivalry and government control. The pharmaceutical business in India meets around 705 of the nation's interest in bulk medications, pharmaceutical formulas, synthetics, tablets, oral and injectables. There are around 250 enormous units and around 8,000 SMUs, which structure the centre of the pharmaceutical business in India, including 4 Pubilc sector units. Looking forward, the worldwide drug store market is assessed at more than to 1.5 billion dollars constantly in 2020. The Indian pharmaceutical industry is growing significantly every year. The primary goal of this research unmistakably demonstrates that pharmaceutical organizations are working great as an industry as well as can add growth to the development of the national economy. In this way, we made an attempt to find the effect of financial performance on profitability.

8 The Law And Economics Of Vertical Restraints

2012 ◽  
Author(s):  
Geradin Damien ◽  
Layne-Farrar Anne ◽  
Petit Nicolas
Keyword(s):  
Law And Economics ◽  
Competition Law ◽  
Legal Framework ◽  
Vertical Restraints ◽  
Economic Approach ◽  
Brand Competition ◽  
Eu Competition Law ◽  
Early Case ◽  
The 1960S ◽  
Independent Distribution

This chapter examines independent distribution and how it is treated under EU competition law. Since the 1960s, it is acknowledged that vertical agreements can entail restrictions of competition—generally called ‘vertical restraints’—which deserve competition law scrutiny. While the early case law and Regulations adopted in the field focused primarily on restrictions of intra-brand competition, a more liberal and economic approach was introduced with the promulgation of Regulation 2790/1999. The new legal framework rested on a basic economic premise: the ability of a vertical agreement to produce anticompetitive effects hinges predominantly on the market power of the parties to the agreement. With the expiry of Regulation 2790/1999 on 31 May 2010, but also with the growth of large retailers throughout Europe and the rise of internet distribution, the Commission initiated a review process in July 2009 which culminated in the adoption of Regulation 330/2010 and of a new set of Guidelines.

Sign in / Sign up

Export Citation Format

Share Document